The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
INTERVENTIONS FOR VALVULAR DISEASE AND HEART FAILURE
Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study
EuroIntervention 2018;13:2003-2011 published online January 2018. DOI: 10.4244/EIJ-D-17-00672
Martin W. Bergmann1*, MD, PhD, FESC; Hüseyin Ince2, MD; Stephan Kische3, MD; Thomas Schmitz4, MD; Felix Meincke5, MD; Boris Schmidt6, MD; David Foley7, MB, BCh, PhD; Timothy R. Betts8, MD; Marek Grygier9, MD; Alexey V. Protopopov10, MD; Kenneth M. Stein11, MD; Lucas V.A. Boersma12, MD
1. Cardiologicum Hamburg, Hamburg, Germany; 2. Abt. Kardiologie, Vivantes Klinikum Am Urban, Berlin, Germany; 3. Abt. Kardiologie, Vivantes Klinikum im Friedrichshain, Berlin, Germany; 4. Abt. Kardiologie, Elisabeth Krankenhaus, Essen, Germany; 5. Abt. Ka
Aims: The study aimed to confirm the efficacy and safety of WATCHMAN LAA closure in atrial fibrillation patients unsuitable for oral anticoagulation.